Mainz Biomed (MYNZ) announced the signing of a Memorandum of Understanding, MOU, with OncoVanguard8, a distributor of oncological innovations. The collaboration aims to introduce ColoAlert, a DNA-based colorectal cancer, CRC, screening test, to South America, starting with Peru.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Mainz Biomed’s Colorectal Cancer Test: A Promising Pilot Study Update
- Mainz Biomed’s Colorectal Cancer Screening Test: A New Hope for Early Detection
- Promising Diagnostic Advances and Strategic Collaborations Justify Buy Rating for Mainz Biomed
- Mainz Biomed reports results from feasibility study of biomarker panel
- Mainz Biomed Enters $10 Million Equity Distribution Agreement with Maxim Group